Health Relay’s cancer drug proves tolerable, but market is unimpressedApril 19, 20230 ORLANDO, Fla. — Researchers introduced early section trial outcomes on RLY-2608, Relay Therapeutics’ next-generation PI3K inhibitor, on the American Affiliation…
